Cyclic Nucleotide Phosphodiesterases, Type 4
"Cyclic Nucleotide Phosphodiesterases, Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
| Descriptor ID |
D054703
|
| MeSH Number(s) |
D08.811.277.352.640.150.400 D12.644.360.008.400 D12.776.476.008.400
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 4- Cyclic Nucleotide Phosphodiesterases, Type 4
- Phosphodiesterase-4
- Phosphodiesterase IV
- PDE4 Phosphodiesterases
- Phosphodiesterases, PDE4
- Cyclic Nucleotide Phosphodiesterase PDE4 Family
- Phosphodiesterase 4
- Type 4 Cyclic Nucleotide Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 4".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med. 2021 05; 27(5):862-870.
-
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs. 2007 Sep; 16(9):1489-506.
-
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
-
Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem. 2004 Dec 10; 279(50):52095-105.